Source link : https://www.newshealth.biz/health-news/sotagliflozin-rejected-for-t1d-thyroid-and-covid-diabetes-drug-price-cut/
The FDA rejected sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease, said maker Lexicon Pharmaceuticals. The decision was expected following a negative FDA advisory committee review in October. Over 40% of Americans say they are overweight, and 55% want to lose weight, […]
Author : News Health
Publish date : 2024-12-31 18:00:00
Copyright for syndicated content belongs to the linked Source.